Zimmer Biomet Holdings Inc (NYSE:ZBH) price target raised to $128.00 by Citigroup

ME Staff
-
0

Analyst Ratings For Zimmer Biomet Holdings Inc (NYSE:ZBH)

Today, Citigroup raised its price target on Zimmer Biomet Holdings Inc (NYSE:ZBH) to $128.00 per share.

There are 15 Buy Ratings, 7 Hold Ratings, 1 Strong Buy Ratings, 1 Sell Ratings on the stock.

The current consensus rating on Zimmer Biomet Holdings Inc (NYSE:ZBH) is Buy with a consensus target price of $135.4286 per share, a potential 7.65% upside.

Some recent analyst ratings include

    Recent Insider Trading Activity For Zimmer Biomet Holdings Inc (NYSE:ZBH)
    Zimmer Biomet Holdings Inc (NYSE:ZBH) has insider ownership of 0.71% and institutional ownership of 87.19%.

    • On 5/22/2018 Katarzyna Mazur-Hofsaess, Insider, sold 8,765 with an average share price of $113.61 per share and the total transaction amounting to $995,791.65.
    • On 4/30/2018 Tony W Collins, VP, sold 1,330 with an average share price of $116.73 per share and the total transaction amounting to $155,250.90.
    • On 2/20/2018 Bryan C Hanson, Insider, bought 25,077 with an average share price of $119.68 per share and the total transaction amounting to $3,001,215.36.
    • On 2/12/2018 Chad F. Phipps, VP, sold 20,826 with an average share price of $115.95 per share and the total transaction amounting to $2,414,774.70.
    • On 7/31/2017 Tony W. Collins, VP, sold 16,986 with an average share price of $121.74 per share and the total transaction amounting to $2,067,875.64.
    • On 6/12/2017 Sang Yi, Insider, sold 17,731 with an average share price of $124.56 per share and the total transaction amounting to $2,208,573.36.
    • On 5/5/2017 Chad F. Phipps, VP, sold 6,200 with an average share price of $116.76 per share and the total transaction amounting to $723,912.00.

    About Zimmer Biomet Holdings Inc (NYSE:ZBH)
    Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including surgical, sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products; and bone cement and spinal fusion stimulators. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopaedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

    Recent Trading Activity for Zimmer Biomet Holdings Inc (NYSE:ZBH)
    Shares of Zimmer Biomet Holdings Inc closed the previous trading session at 125,90 −0,64 0,51 % with 125.46 shares trading hands.